LGND - Ligand Pharmaceuticals Incorporated
NASDAQ
->
Healthcare
->
Biotechnology
EmeryVille,
United States
Type: Equity
LGND price evolution
LGND
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $22.95 | $19.27 | $28.45 | $88.73 |
| Short term investments | $171.23 | $190.6 | $193.94 | |
| Net receivables | $32.92 | $36 | $27.99 | $29.19 |
| Inventory | $23.97 | $25.39 | $26.91 | $14.01 |
| Total current assets | $237.43 | $253.99 | $276.71 | $328.19 |
| Long term investments | $48.32 | $47.08 | ||
| Property, plant & equipment | $25.06 | $25.98 | $26.54 | $27.35 |
| Goodwill & intangible assets | $470.27 | $425.21 | $441.83 | $450.02 |
| Total noncurrent assets | $549.79 | $515.23 | $481.39 | $482.88 |
| Total investments | $147.35 | $218.31 | $190.6 | $193.94 |
| Total assets | $787.22 | $769.23 | $758.11 | $811.08 |
| Current liabilities | ||||
| Accounts payable | $2.43 | $2.48 | $9.58 | $6.13 |
| Deferred revenue | $2.67 | $0.26 | ||
| Short long term debt | $0.41 | $0.5 | $0.68 | $77.49 |
| Total current liabilities | $16.78 | $15.73 | $29.39 | $98.93 |
| Long term debt | $5.75 | $5.83 | $10.99 | $11.18 |
| Total noncurrent liabilities | $69.52 | $85.6 | $63.83 | $65.83 |
| Total debt | $6.17 | $6.33 | $11.67 | $88.68 |
| Total liabilities | $86.3 | $101.33 | $93.21 | $164.76 |
| Shareholders' equity | ||||
| Retained earnings | $503.02 | $484.83 | $495.1 | $492.81 |
| Other shareholder equity | -$0.82 | -$0.94 | -$0.97 | -$0.94 |
| Total shareholder equity | $700.91 | $667.9 | $664.89 | $646.32 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $22.95 | $45.01 | $19.52 | $47.62 |
| Short term investments | $166.86 | $321.59 | $363.57 | |
| Net receivables | $32.92 | $35.04 | $85.45 | $56.85 |
| Inventory | $23.97 | $13.29 | $27.33 | $26.49 |
| Total current assets | $237.43 | $263.6 | $464.75 | $500.56 |
| Long term investments | $48.32 | |||
| Property, plant & equipment | $25.06 | $15.01 | $53.26 | $37.17 |
| Goodwill & intangible assets | $470.27 | $458.31 | $742.36 | $795.97 |
| Total noncurrent assets | $549.79 | $499.07 | $832.84 | $861.73 |
| Total investments | $147.35 | $166.86 | $321.59 | $363.57 |
| Total assets | $787.22 | $762.67 | $1297.59 | $1362.29 |
| Current liabilities | ||||
| Accounts payable | $2.43 | $20.99 | $8.4 | $3.78 |
| Deferred revenue | $2.67 | $0.35 | $11 | $29.43 |
| Short long term debt | $0.41 | $77.41 | $2.1 | $8.48 |
| Total current liabilities | $16.78 | $98.81 | $41.66 | $100.11 |
| Long term debt | $5.75 | $10.34 | $336.21 | $447.94 |
| Total noncurrent liabilities | $69.52 | $66.37 | $434.77 | $552.65 |
| Total debt | $6.17 | $87.75 | $338.31 | $456.41 |
| Total liabilities | $86.3 | $165.18 | $476.43 | $652.76 |
| Shareholders' equity | ||||
| Retained earnings | $503.02 | $450.86 | $449.09 | $391.95 |
| Other shareholder equity | -$0.82 | $597.49 | -$0.92 | -$0.8 |
| Total shareholder equity | $700.91 | $597.49 | $821.16 | $709.52 |
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $28.1 | $32.87 | $26.37 | $43.98 |
| Cost of revenue | $3.48 | $1.67 | $3.72 | |
| Gross Profit | $26.46 | $29.38 | $24.7 | $40.26 |
| Operating activities | ||||
| Research & development | $5.53 | $6.85 | $6.66 | |
| Selling, general & administrative | $14.66 | $11.29 | $10.86 | |
| Total operating expenses | $29.82 | $26.3 | $26.68 | $26.06 |
| Operating income | $3.08 | -$1.98 | $14.21 | |
| Income from continuing operations | ||||
| EBIT | -$12.14 | $3.46 | $54.11 | |
| Income tax expense | -$1.09 | -$1.87 | $0.88 | $11.92 |
| Interest expense | $17.84 | $0 | $0.28 | $0.24 |
| Net income | ||||
| Net income | $18.19 | -$10.27 | $2.29 | $41.95 |
| Income (for common shares) | -$10.27 | $2.29 | $41.95 | |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $131.31 | $196.25 | $186.42 | |
| Cost of revenue | $52.83 | $30.42 | ||
| Gross Profit | $120.8 | $143.42 | $156 | |
| Operating activities | ||||
| Research & development | $36.08 | $59.39 | ||
| Selling, general & administrative | $70.06 | $64.44 | ||
| Total operating expenses | $110.98 | $140.38 | $130.16 | |
| Operating income | $3.04 | $25.84 | ||
| Income from continuing operations | ||||
| EBIT | $9.67 | $16.88 | ||
| Income tax expense | $9.84 | $41.23 | -$7.55 | |
| Interest expense | $53.67 | $1.8 | $27.42 | |
| Net income | ||||
| Net income | $52.15 | -$33.36 | -$2.98 | |
| Income (for common shares) | -$33.36 | -$2.98 | ||
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$10.27 | $2.29 | $41.95 | |
| Operating activities | ||||
| Depreciation | $8.95 | $9.95 | $9.95 | |
| Business acquisitions & disposals | -$25.64 | |||
| Stock-based compensation | $6.88 | $7.21 | $5.93 | |
| Total cash flows from operations | $7.65 | -$0.08 | $33.95 | |
| Investing activities | ||||
| Capital expenditures | -$0.35 | -$0.12 | -$2.28 | |
| Investments | $6.49 | $7.68 | $12.83 | |
| Total cash flows from investing | -$11.68 | -$19.5 | $7.56 | $10.55 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.39 | $9.14 | $3.39 | |
| Net borrowings | -$76.84 | -$0.01 | ||
| Total cash flows from financing | -$59.98 | $3.27 | -$67.76 | -$0.78 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$22.1 | -$8.59 | -$60.28 | $43.72 |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$33.36 | $57.14 | -$2.98 | |
| Operating activities | ||||
| Depreciation | $56.89 | $50.95 | $27.97 | |
| Business acquisitions & disposals | -$385.15 | |||
| Stock-based compensation | $60.28 | $38.78 | $29.25 | |
| Total cash flows from operations | $137.85 | $78.8 | $54.59 | |
| Investing activities | ||||
| Capital expenditures | -$17.83 | -$8.27 | -$3.1 | |
| Investments | $182.41 | $40.01 | $615.67 | |
| Total cash flows from investing | -$11.68 | $163.62 | $30.52 | $231.65 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.23 | $33.76 | -$74.98 | |
| Net borrowings | -$260.8 | -$146.01 | -$231.76 | |
| Total cash flows from financing | -$59.95 | -$275.99 | -$137.76 | -$310.55 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$22.05 | $25.48 | -$28.44 | -$24.31 |
News
Fundamentals
| Market cap | $1.40B |
|---|---|
| Enterprise value | $1.38B |
| Shares outstanding | 17.56M |
| Revenue | $131.31M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $52.15M |
| Revenue Q/Q | 3.90% |
| Revenue Y/Y | N/A |
| P/E ratio | 26.85 |
|---|---|
| EV/Sales | 10.54 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 10.66 |
| P/B ratio | 2.00 |
| Book/Share | 39.97 |
| Cash/Share | 1.31 |
| EPS | $2.97 |
|---|---|
| ROA | 6.67% |
| ROE | 7.78% |
| Debt/Equity | 0.12 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 14.15 |
| Quick ratio | 12.72 |